TN2009000268A1 - Substituted isoquinoline and isoquinolinone derivatives - Google Patents

Substituted isoquinoline and isoquinolinone derivatives

Info

Publication number: TN2009000268A1
Authority: TN; Tunisia
Prior art keywords: substituted isoquinoline; isoquinolinone derivatives; derivatives; rho; kinase
Prior art date: 2006-12-27

Application number

TNP2009000268A

Other languages

English (en)

Inventor

Olivier Plettenburg

Armin Hofmeister

Jochen Goerlitzer

Matthias Lohn

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-27

Filing date

2009-06-25

Publication date

2010-10-18

2009-06-25 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2010-10-18 Publication of TN2009000268A1 publication Critical patent/TN2009000268A1/fr

Links

VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 title abstract 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 1
150000002537 isoquinolines Chemical class 0.000 title 1
102000000568 rho-Associated Kinases Human genes 0.000 abstract 2
108010041788 rho-Associated Kinases Proteins 0.000 abstract 2
-1 6-substituted isoquinoline Chemical class 0.000 abstract 1
102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 abstract 1
108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000026731 phosphorylation Effects 0.000 abstract 1
238000006366 phosphorylation reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)

TNP2009000268A 2006-12-27 2009-06-25 Substituted isoquinoline and isoquinolinone derivatives TN2009000268A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06026896		2006-12-27
PCT/EP2007/011165 WO2008077552A1 (fr)	2006-12-27	2007-12-19	Dérivés d'isoquinoline et d'isoquinolinone substitués

Publications (1)

Publication Number	Publication Date
TN2009000268A1 true TN2009000268A1 (en)	2010-10-18

Family

ID=38001966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000268A TN2009000268A1 (en)	2006-12-27	2009-06-25	Substituted isoquinoline and isoquinolinone derivatives

Country Status (22)

Country	Link
US (1)	US8748614B2 (fr)
EP (1)	EP2114920A1 (fr)
JP (1)	JP5405315B2 (fr)
KR (1)	KR20090094338A (fr)
CN (1)	CN101573353B (fr)
AU (1)	AU2007338408B2 (fr)
BR (1)	BRPI0720986A2 (fr)
CA (1)	CA2673918C (fr)
CO (1)	CO6210826A2 (fr)
CR (1)	CR10814A (fr)
DO (1)	DOP2009000162A (fr)
EC (1)	ECSP099470A (fr)
IL (1)	IL199537A (fr)
MA (1)	MA31022B1 (fr)
MX (1)	MX2009006517A (fr)
MY (1)	MY155279A (fr)
NO (1)	NO20092424L (fr)
RU (1)	RU2009128693A (fr)
SV (1)	SV2009003312A (fr)
TN (1)	TN2009000268A1 (fr)
WO (1)	WO2008077552A1 (fr)
ZA (1)	ZA200903552B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007008926A1 (fr)	2005-07-11	2007-01-18	Aerie Pharmaceuticals, Inc.	Composes isoquinoliniques
JP5235887B2 (ja)	2006-09-20	2013-07-10	アエリーファーマシューティカルズインコーポレイテッド	Ｒｈｏキナーゼ阻害剤
US8455513B2 (en)	2007-01-10	2013-06-04	Aerie Pharmaceuticals, Inc.	6-aminoisoquinoline compounds
US8455514B2 (en)	2008-01-17	2013-06-04	Aerie Pharmaceuticals, Inc.	6-and 7-amino isoquinoline compounds and methods for making and using the same
BRPI0914330A2 (pt) *	2008-06-24	2019-09-24	Sanofi Aventis	derivados de isoquinolina e isoquinolinona substituídos bl-e policíclicos
PE20110054A1 (es) *	2008-06-24	2011-02-15	Sanofi Aventis	Isoquinolinas e isoquinolinonas 6-sustituidas
WO2009156100A1 (fr) *	2008-06-24	2009-12-30	Sanofi-Aventis	Isoquinolines et isoquinolinones substituées utilisées comme inhibiteurs de rho-kinase
US8410147B2 (en)	2008-06-26	2013-04-02	Inspire Pharmaceuticals, Inc.	Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
EP2317849A4 (fr) *	2008-06-26	2011-11-02	Inspire Pharmaceuticals Inc	Procédé permettant de traiter des maladies pulmonaires par des composés inhibiteurs de rho kinase
US8450344B2 (en)	2008-07-25	2013-05-28	Aerie Pharmaceuticals, Inc.	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2929545C (fr)	2009-05-01	2019-04-09	Aerie Pharmaceuticals, Inc.	Inhibiteurs a mecanisme double pour le traitement de maladie
US20140275160A1 (en)	2013-03-15	2014-09-18	Aerie Pharmaceuticals, Inc.	Combination therapy
RU2709482C1 (ru) *	2013-12-20	2019-12-18	Эстеве Фармасьютикалз, С.А.	Производные пиперазина, характеризующиеся мультимодальной активностью в отношении боли
FR3017868A1 (fr)	2014-02-21	2015-08-28	Servier Lab	Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105085478B (zh) *	2014-04-28	2019-04-12	南京明德新药研发股份有限公司	异喹啉磺胺衍生物及其药物组合物和制药用途
DK3194403T3 (en)	2014-09-15	2019-04-15	Rugen Holdings Cayman Ltd	PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS
EP3253761A4 (fr)	2015-02-04	2018-06-20	Rugen Holdings (Cayman) Limited	Dérivés 3,3-difluoro-pipéridine en tant qu'antagonistes des récepteurs nmda nr2b
JP6876625B2 (ja) *	2015-06-01	2021-05-26	リューゲンホールディングス（ケイマン）リミテッド	Ｎｒ２ｂｎｍｄａレセプターアンタゴニストとしての３，３−ジフルオロピペリジンカルバメート複素環式化合物
CN105237474B (zh) *	2015-09-30	2017-08-29	沈阳药科大学	6‑羟基‑7‑芳甲酰基喹啉酮类化合物的制备及其应用
US9643927B1 (en)	2015-11-17	2017-05-09	Aerie Pharmaceuticals, Inc.	Process for the preparation of kinase inhibitors and intermediates thereof
JP6832946B2 (ja)	2015-11-17	2021-02-24	アエリエファーマシューティカルズインコーポレイテッド	キナーゼ阻害剤およびその中間体の調製方法
CN118873533A (zh)	2016-08-31	2024-11-01	爱尔康公司	眼用组合物
EP3544610A1 (fr)	2016-11-22	2019-10-02	Rugen Holdings (Cayman) Limited	Traitement de troubles du spectre autistique, de troubles obsessivo-compulsifs et de troubles de l'anxiété
JP2020515583A (ja)	2017-03-31	2020-05-28	アエリエファーマシューティカルズインコーポレイテッド	アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
WO2020056345A1 (fr)	2018-09-14	2020-03-19	Aerie Pharmaceuticals, Inc.	Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
CN109180586B (zh) *	2018-10-10	2022-03-08	成都理工大学	作为Rho激酶抑制剂的六氢氮杂卓-4-基氧基苯甲酰胺类化合物
CA3116347A1 (fr)	2018-10-31	2020-05-07	Gilead Sciences, Inc.	Composes 6-azabenzimidazole substitues ayant une activite inhibitrice de hpk1
PE20211655A1 (es)	2018-10-31	2021-08-24	Gilead Sciences Inc	Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
WO2020237025A1 (fr)	2019-05-23	2020-11-26	Gilead Sciences, Inc.	Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2485537B2 (fr) *	1977-04-13	1986-05-16	Anvar	Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
JPH06501921A (ja)	1990-07-31	1994-03-03	イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー	選択されたハロカーボンの触媒平衡化
US5480883A (en) *	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en)	1995-08-15	1995-10-18	Zeneca Ltd	Medicament
ZA9610741B (en)	1995-12-22	1997-06-24	Warner Lambert Co	4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
BR9711154A (pt)	1996-08-12	1999-08-17	Yoshitomi Pharmaceutical	Agente farmac-utico contendo inibidor cinase rho
JPH1087629A (ja)	1996-09-18	1998-04-07	Fujisawa Pharmaceut Co Ltd	新規イソキノリン誘導体、およびその医薬用途
US6362191B1 (en)	1997-08-29	2002-03-26	Zeneca Ltd.	Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) *	1998-10-23	2004-02-11	Akzo Nobel Nv	Serine protease inhibitor
GB9912701D0 (en)	1999-06-01	1999-08-04	Smithkline Beecham Plc	Novel compounds
US6541456B1 (en)	1999-12-01	2003-04-01	Isis Pharmaceuticals, Inc.	Antimicrobial 2-deoxystreptamine compounds
US6784192B2 (en)	2000-01-20	2004-08-31	Eisai Co., Ltd.	Piperidine compound and pharmaceutical composition thereof
US7217722B2 (en) *	2000-02-01	2007-05-15	Kirin Beer Kabushiki Kaisha	Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001239947A1 (en)	2000-02-29	2001-09-12	Curis, Inc.	Methods and compositions for regulating adipocytes
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
AR033517A1 (es)	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en)	2000-05-31	2000-07-19	Astrazeneca Ab	Chemical compounds
WO2002034712A1 (fr)	2000-10-27	2002-05-02	Takeda Chemical Industries, Ltd.	Procede de preparation de composes aromatiques substitues et produits intermediaires associes
WO2002055496A1 (fr)	2001-01-15	2002-07-18	Glaxo Group Limited	Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl
SE0101038D0 (sv)	2001-03-23	2001-03-23	Astrazeneca Ab	Novel compounds
WO2002088101A2 (fr)	2001-04-27	2002-11-07	Vertex Pharmaceuticals Incorporated	Inhibiteurs de bace
WO2002100833A1 (fr) *	2001-06-12	2002-12-19	Sumitomo Pharmaceuticals Company, Limited	Inhibiteurs de rho kinase
GB0117899D0 (en)	2001-07-23	2001-09-12	Astrazeneca Ab	Chemical compounds
WO2003024450A1 (fr)	2001-09-20	2003-03-27	Eisai Co., Ltd.	Methodes de traitement des maladies a prions
SE0104340D0 (sv)	2001-12-20	2001-12-20	Astrazeneca Ab	New compounds
EP1541559A4 (fr)	2002-07-22	2007-08-22	Asahi Kasei Pharma Corp	Derive d'isoquinoline 5-substituee
CN100383140C (zh)	2002-09-12	2008-04-23	麒麟麦酒株式会社	具有激酶抑制活性的异喹啉衍生物和包含异喹啉衍生物的药剂
WO2004105757A2 (fr)	2003-05-29	2004-12-09	Schering Aktiengesellschaft	Utilisation des inhibiteurs de la rho kinase dans le traitement de l'anevrisme et de l'hypertrophie cardiaque
US20070021404A1 (en)	2003-06-24	2007-01-25	Dan Peters	Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1667982B1 (fr)	2003-09-23	2013-07-31	Merck Sharp & Dohme Corp.	Inhibiteurs du canal potassique d'isoquinolinone
CA2539479C (fr)	2003-09-23	2010-07-06	Merck & Co., Inc.	Inhibiteurs des canaux potassiques a l'isoquinoleine
US20050067037A1 (en)	2003-09-30	2005-03-31	Conocophillips Company	Collapse resistant composite riser
EP1671962A1 (fr)	2003-10-10	2006-06-21	Ono Pharmaceutical Co., Ltd.	Nouveau compose heterocyclique fondu et utilisation correspondante
US7449477B2 (en)	2003-11-25	2008-11-11	Eli Lilly And Company	7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
JP2005232175A (ja) *	2004-01-21	2005-09-02	Asahi Kasei Pharma Kk	５−置換イソキノリン医薬
WO2005074535A2 (fr)	2004-01-30	2005-08-18	Eisai Co., Ltd.	Inhibiteurs de cholinesterase pour des troubles de la colonne vertebrale
EP1729761A4 (fr)	2004-03-05	2008-09-03	Eisai Co Ltd	Traitement de cadasil avec des inhibiteurs de la cholinesterase
SE0400850D0 (sv)	2004-03-30	2004-03-31	Astrazeneca Ab	Novel Compounds
US7517991B2 (en) *	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
ES2372067T3 (es)	2005-07-26	2012-01-13	Sanofi	Derivados de ciclohexilamina isoquinolona como inhibidores de la rho-quinasa.
KR101373535B1 (ko)	2005-07-26	2014-03-12	사노피	Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체
TW200745101A (en)	2005-09-30	2007-12-16	Organon Nv	9-Azabicyclo[3.3.1]nonane derivatives
TW200738682A (en) *	2005-12-08	2007-10-16	Organon Nv	Isoquinoline derivatives
US7618985B2 (en) *	2005-12-08	2009-11-17	N.V. Organon	Isoquinoline derivatives
US7511063B2 (en) *	2006-08-16	2009-03-31	Schering Corporation	High affinity quinoline-based kinase ligands
US7893088B2 (en)	2006-08-18	2011-02-22	N.V. Organon	6-substituted isoquinoline derivatives
PL2102164T3 (pl)	2006-12-27	2011-05-31	Sanofi Aventis	Pochodne izochinoliny i izochinolinonu podstawione cykloalkiloaminami
MX2009005862A (es)	2006-12-27	2009-06-17	Sanofi Aventis	Nuevos derivados de isoquinolina e isoquinolinona sustituidos.

2007
- 2007-12-19 RU RU2009128693/04A patent/RU2009128693A/ru not_active Application Discontinuation
- 2007-12-19 EP EP07856888A patent/EP2114920A1/fr not_active Withdrawn
- 2007-12-19 JP JP2009543373A patent/JP5405315B2/ja not_active Expired - Fee Related
- 2007-12-19 CN CN200780048282.0A patent/CN101573353B/zh not_active Expired - Fee Related
- 2007-12-19 MX MX2009006517A patent/MX2009006517A/es active IP Right Grant
- 2007-12-19 MY MYPI20092505A patent/MY155279A/en unknown
- 2007-12-19 BR BRPI0720986-0A patent/BRPI0720986A2/pt not_active IP Right Cessation
- 2007-12-19 KR KR1020097013517A patent/KR20090094338A/ko not_active Abandoned
- 2007-12-19 CA CA2673918A patent/CA2673918C/fr not_active Expired - Fee Related
- 2007-12-19 AU AU2007338408A patent/AU2007338408B2/en not_active Ceased
- 2007-12-19 WO PCT/EP2007/011165 patent/WO2008077552A1/fr active Application Filing
2009
- 2009-05-20 CR CR10814A patent/CR10814A/es not_active Application Discontinuation
- 2009-05-22 ZA ZA200903552A patent/ZA200903552B/xx unknown
- 2009-06-16 CO CO09062102A patent/CO6210826A2/es not_active Application Discontinuation
- 2009-06-18 US US12/487,455 patent/US8748614B2/en not_active Expired - Fee Related
- 2009-06-23 SV SV2009003312A patent/SV2009003312A/es unknown
- 2009-06-24 IL IL199537A patent/IL199537A/en not_active IP Right Cessation
- 2009-06-24 MA MA32037A patent/MA31022B1/fr unknown
- 2009-06-25 NO NO20092424A patent/NO20092424L/no not_active Application Discontinuation
- 2009-06-25 TN TNP2009000268A patent/TN2009000268A1/fr unknown
- 2009-06-26 DO DO2009000162A patent/DOP2009000162A/es unknown
- 2009-06-26 EC EC2009009470A patent/ECSP099470A/es unknown

Also Published As

Publication number	Publication date
MX2009006517A (es)	2009-06-26
US20100105650A1 (en)	2010-04-29
US8748614B2 (en)	2014-06-10
MY155279A (en)	2015-09-30
IL199537A (en)	2013-11-28
MA31022B1 (fr)	2009-12-01
WO2008077552A1 (fr)	2008-07-03
CO6210826A2 (es)	2010-10-20
RU2009128693A (ru)	2011-02-10
CA2673918A1 (fr)	2008-07-03
AU2007338408A1 (en)	2008-07-03
CA2673918C (fr)	2015-02-17
SV2009003312A (es)	2010-02-05
ECSP099470A (es)	2009-07-31
DOP2009000162A (es)	2009-07-31
NO20092424L (no)	2009-09-18
JP5405315B2 (ja)	2014-02-05
CN101573353B (zh)	2014-08-06
BRPI0720986A2 (pt)	2014-03-11
KR20090094338A (ko)	2009-09-04
CN101573353A (zh)	2009-11-04
CR10814A (es)	2009-08-12
ZA200903552B (en)	2010-04-28
IL199537A0 (en)	2010-03-28
AU2007338408B2 (en)	2012-07-26
JP2010514717A (ja)	2010-05-06
EP2114920A1 (fr)	2009-11-11

Publication	Publication Date	Title
TN2009000268A1 (en)	2010-10-18	Substituted isoquinoline and isoquinolinone derivatives
TN2009000273A1 (en)	2010-10-18	New substituted isoquinoline and isoquinolinone derivatives
MY154767A (en)	2015-07-15	Cycloalkyamine substituted isoquinoline and isoquinolinone derivatives
MY150746A (en)	2014-02-28	Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
TN2009000269A1 (en)	2010-10-18	Cycloalkylamine substituted isoquinolone derivatives
HK1140189A1 (en)	2010-10-08	Cycloalkylamine substituted isoquinoline derivatives
CO6210725A2 (es)	2010-10-20	Derivados de isoquinolona e isoquinolinona sustituidos con cicloalquilamina
TW200738678A (en)	2007-10-16	Isoquinoline derivatives
TNSN08039A1 (en)	2009-07-14	Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
MY146644A (en)	2012-09-14	Cyclohexylamin isoquinolone derivatives
AU2009262516A8 (en)	2014-01-30	6-substituted isoquinolines and isoquinolinones
TN2010000588A1 (en)	2012-05-24	Substituted isoquinolines and isoquinolinones